Kyle Doherty

Articles

Celularity and Imugene Enter into Potentially ‘Game-Changing’ Collaboration

November 18th 2021

Chimeric antigen receptor T-cell therapies are rapidly shifting the treatment paradigm for a multitude of hematologic malignancies.

Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative

November 16th 2021

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

Novel ADC Appears to Leverage TROP2 Expression in NSCLC

November 16th 2021

Investigators aim to expand the treatment portfolio with the phase 3 TROPION-LUNG01 trial, which is designed to examine datopotamab deruxtecan vs docetaxel in patients with advanced or metastatic NSCLC without actionable genomic alterations who have previously received platinum-based chemotherapy and immunotherapy. 

Lenvatinib Plus Pembrolizumab Displays Strong Efficacy in Advanced Endometrial Cancer

November 15th 2021

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

Enhanced Grasp of Oncogenic Drivers Leads to Expanded Treatment Options in NSCLC

November 9th 2021

An increased understanding of the biology of non–small cell lung cancer has led to a significant increase in therapeutic options for patients.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

COVID-19 Vaccination Remains Imperative for Patients with Cancer

November 4th 2021

As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.

Treatment Options Continue to Increase in Low-Risk MDS

November 3rd 2021

Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.

The Multifaceted Threat of Cyberattacks in Oncology

November 1st 2021

Diego Adrianzen Herrera, MD, shares his experience with a cyberattack at the University of Vermont Health Network and its effect on inpatient and outpatient care delivery.

First-Line Durvalumab Aims to Add Additional Treatment Option in Malignant Pleural Mesothelioma

October 29th 2021

Investigators look to boost systemic therapy options for patients with malignant pleural mesothelioma with the phase 3 DREAM3R trial.

Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer

October 27th 2021

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Cemiplimab Expands Treatment Portfolio for Patients with Basal Cell Carcinoma

October 27th 2021

Alexander J. Stratigos, MD, PhD, discussed the effect cemiplimab will have on the treatment landscape of patients with advanced BCC.

Cemiplimab Earns High Marks in First-Line Treatment of Advanced NSCLC

October 18th 2021

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial

October 14th 2021

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

Onvansertib Combination Aims to Improve Poor Prognosis in PDAC

October 7th 2021

Patients with pancreatic ductal adenocarcinoma experience limited benefit with available first- and second-line second line of therapy.

Lenvatinib Plus Pembrolizumab Makes an Impression in Advanced RCC

October 6th 2021

Robert J. Motzer, MD, spoke about the “exceptional” efficacy of the combination and how it fits into the evolving RCC treatment landscape.

Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma Treatment

September 27th 2021

Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer

September 17th 2021

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Promising Results Push Nivolumab/Chemotherapy Forward in Gastric Cancer

September 15th 2021

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.